Terms ending in 2043
Every in-force patent on Codiak Biosciences, Inc.'s record whose computed term ends in 2043, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,545,728 | Treatment of Cancer Metastasis by Targeting Exosome Proteins In force · High confidence | Lonza Sales AG | In force | High confidence | |
| US 12,758,896 | High-Throughput Chromatography Screening for Extracellular Vesicles In force · High confidence | Lonza Sales AG | In force | High confidence | |
| US 12,616,712 | Sting Agonist Comprising Exosomes for Treating Neuroimmunological Disorders In force · High confidence | Lonza Sales AG | In force | High confidence | |
| US 12,648,907 | Membrane Protein Scaffolds for Exosome Engineering In force · High confidence | Lonza Sales AG | In force | High confidence | |
| US 12,728,098 | Methods of Producing Extracellular Vesicles In force · High confidence | Lonza Sales AG | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Codiak Biosciences, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.